Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Sanofi507 enrolled

Overview

Primary Objective: To demonstrate non-inferiority of SAR342434 versus Humalog in glycated haemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 diabetes mellitus (T1DM) also using insulin glargine. Secondary Objectives: To assess the immunogenicity of SAR342434 and Humalog in terms of positive/negative status and antibody titers at baseline and during the course of the study. To assess the relationship of anti-insulin antibodies with efficacy and safety including during the safety extension. To assess the efficacy of SAR342434 and Humalog in terms of proportion of participants reaching target HbA1c (\<7%), Fasting plasma glucose (FPG), self-measured plasma glucose (SMPG) profiles, and insulin dose. To assess safety of SAR342434 and Humalog.

The study consisted of a: * Up to 2 weeks screening period * 26-week treatment period * 26-week comparative safety extension period * 1-day follow-up period * The maximum study duration would be 54 weeks per participant and a 1-day safety follow-up

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

507

Conditions

Type 1 Diabetes Mellitus

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Participants with T1DM diagnosed for at least 12 months and had been treated with insulin glargine and Humalog or Novolog®/Novo Rapid® (at least 3 times daily before each meal) in the 6 months prior to the screening visit. * Written informed consent. Exclusion criteria: * At screening visit, age under legal age of adulthood. * HbA1c \<7.0% or \>10% at screening. * Diabetes other than T1DM. * Status post pancreatectomy. * Status post pancreas and/or islet cell transplantation. * Pregnancy and lactation. * Women of childbearing potential not protected by highly effective contraceptive method of birth control. * Less than 1 year on continuous insulin treatment. * Use of insulin pump in the last 6 months before screening visit. * Use of glucose lowering treatments other than insulin including non-insulin injectable peptides in the last 6 months prior to screening visit. * Use of insulin other than insulin glargine and Humalog or Novolog/Novo Rapid as part of a multiple injection regimen (3 to 4 injections per day) in the last 6 months before screening visit. Liprolog® is a European Union approved insulin lispro and is allowed in those countries where it is marketed. * Hospitalization for diabetic ketoacidosis in the last 6 months before screening visit. * Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (89)

Investigational Site Number 840049

Tucson, Arizona, United States

Investigational Site Number 840016

Bell Gardens, California, United States

Investigational Site Number 840048

Chula Vista, California, United States

Investigational Site Number 840046

Concord, California, United States

Investigational Site Number 840039

Fresno, California, United States

Outcomes

Primary Outcomes

Change in HbA1c From Baseline to Week 26

Change in HbA1c was calculated by subtracting baseline value from Week 26 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the main 6-month period and adequate contrasts at Week 26.

Time frame: Baseline, Week 26

Secondary Outcomes

Percentage of Participants With HbA1c <7.0% at Week 26

Participants who had no available assessment for HbA1c at Week 26 were considered as non-responders.

Time frame: Week 26

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26

Change in FPG was calculated by subtracting baseline value from Week 26 value. Adjusted least squares means and standard errors were obtained from a MMRM approach to account for missing data, using all post-baseline FPG data available during the main 6-month period and adequate contrasts at Week 26.

Time frame: Baseline, Week 26

Change in Mean 24-Hour Plasma Glucose Concentration From Baseline to Week 26

Mean 24-hour plasma glucose concentration was calculated based on 7-point self-measured plasma glucose (SMPG) profiles with plasma glucose measurements before and 2-hours after each main meal and at bedtime. Mean 24-hour plasma glucose concentration was calculated for each profile and then averaged across profiles performed in week before a visit. Change in mean 24-hour plasma glucose concentration was calculated by subtracting baseline value from Week 26 value. Adjusted least squares means and standard errors were obtained from a MMRM to account for missing data, using all post-baseline data available during the main 6-month period and adequate contrasts at Week 26.

Time frame: Baseline, Week 26

Change in Post Prandial Plasma Glucose (PPG) Excursion From Baseline to Week 26

Plasma glucose excursions were calculated at breakfast, lunch and dinner for each 7-point SMPG profile, as 2-hour PPG minus plasma glucose value obtained 30 minutes prior to start of the meal. Values of plasma glucose excursions at each visit were then calculated as average across the profiles performed in the week before the visit. Change in PPG excursions was calculated by subtracting baseline value from Week 26 value. Adjusted least squares means and standard errors were obtained from a MMRM to account for missing data, using all post-baseline data available during the main 6-month period and adequate contrasts at Week 26.

Time frame: Baseline, Week 26

Number of Hypoglycemia Events (Any Hypoglycemia, Documented Symptomatic Hypoglycemia and Severe Hypoglycemia) Per Participant-Year

Number of treatment-emergent hypoglycemia events per participant-year of exposure were reported. Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia was an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=70 mg/dL (3.9 mmol/L). Hypoglycemic episodes with plasma glucose of 54 mg/dL (\<3.0 mmol/L) were also analyzed.

Time frame: First dose of study drug up to 1 day after the last dose administration (maximum treatment exposure: 400 days)

Percentage of Participants With Hypersensitivity Reactions and Injection Site Reactions

Percentage of participants with hypersensitivity reactions and injection site reactions were reported.

Time frame: First dose of study drug up to 1 day after the last dose administration (maximum treatment exposure: 400 days)

Percentage of Participants With Treatment Emergent Anti-insulin Antibodies (AIAs)

Participants with treatment-emergent AIA (incidence) were reported (as participants with treatment-boosted or treatment-induced AIAs). Participants with treatment-induced AIAs were those who developed AIA following IMP administration (participants with at least one positive AIA sample at any time during on-treatment period, in those participants without pre-existing AIA or with missing baseline sample). Participants with treatment-boosted AIAs were those with pre-existing AIAs that were boosted to a significant higher titer following IMP administration (participants with at least one AIA sample with at least a 4-fold increase in titers compared to baseline value at any time during on-treatment period, in those participants with pre-existing AIA).

Time frame: First dose of study drug up to 1 day after the last dose administration (maximum treatment exposure: 400 days)